Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach

In conclusion, pharmacogenetic treatment allocation of AUD patients to naltrexone, based onOPRM1 genotype, can be a cost-effective strategy, and could have potential individual and societal benefits. However, more evidence on the impact of genotype-guided treatment allocation on relapse is needed to substantiate these conclusions, as there is contradictory evidence about the effectiveness ofOPRM1 genotyping.Eur Addict Res 2018;24:245 –254
Source: European Addiction Research - Category: Addiction Source Type: research
More News: Addiction | Alcoholism | Study